1 |
ClinicalTrials.gov (NCT04267640) A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects Who Have Peripheral Ischemic Ulcers of the Lower Extremity. U.S.National Institutes of Health.
|
2 |
Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther. 2010 Sep;17(9):1152-61.
|
3 |
Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur J Cardiothorac Surg. 2008 Oct;34(4):857-63.
|
4 |
Clinical pipeline report, company report or official report of ViroMed.
|
5 |
Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery-Associated Acute Kidney Injury. Kidney Int Rep. 2020 Sep 25;5(12):2325-2332.
|
6 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
7 |
Targeting MET in cancer: rationale and progress.Nat Rev Cancer.2012 Jan 24;12(2):89-103.
|
8 |
Clinical pipeline report, company report or official report of Amgen (2009).
|
9 |
How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
|
|
|
|
|
|
|